Drug Profile
Research programme: elongation factor 2 kinase inhibitors - Longevica Pharmaceuticals
Alternative Names: Research programme: EF2 kinase inhibitors - Longevica PharmaceuticalsLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Longevica Pharmaceuticals
- Class
- Mechanism of Action Elongation factor 2 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chemotherapy-induced damage
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Chemotherapy induced damage (Prevention) in USA
- 24 Nov 2008 Preclinical trials in Chemotherapy induced damage (Prevention) in USA (unspecified route)